Archive for April, 2014

Investigating the acquisition of Pepco Holdings Inc.

Tripp Levy PLLC investigating the acquisition of Pepco Holdings Inc.

April 30, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Pepco Holdings Inc. (POM) on behalf of its shareholders. Exelon Corporation (EXC) and Pepco announced that they have signed a merger agreement under which Exelon will acquire all the outstanding common stock of Pepco for $27.25 per share in cash.

The investigation concerns whether the senior management and board of directors of Pepco breached their fiduciary duties to shareholders by not engaging in a full and fair process and auction to insure that its shareholders received the maximum value for their shares while not obtaining personal benefits for their own in self-interests not being shared with other shareholders.

If you would like additional information as to how this acquisition of Pepco affects your rights as a shareholder, please contact us toll free at 1-877-772-3975 or contact us via our website.

Investigating Acquisition of Furiex Pharmaceuticals, Inc.

Tripp Levy PLLC investigating the acquisition of Furiex Pharmaceuticals, Inc.

April 28, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX). Forest Laboratories, Inc. (FRX) and Furiex Pharmaceuticals, Inc. (FURX) today announced that Forest has entered into a definitive agreement to acquire Furiex for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval.

If eluxadoline receives FDA approval and is not scheduled as a controlled drug by the DEA, holders of the CVR will receive $30 per share or approximately $360 million in the aggregate. If eluxadoline is designated as a Schedule 4 or Schedule 5 controlled drug by the DEA, holders of the CVR will receive $10 per share (approximately $120 million in the aggregate) or $20 per share (approximately $240 million in the aggregate), respectively.

The investigation concerns whether the board of directors of Furiex enaged in a full and fair auction and process to insure that shareholders received the maximum value. Indeed, analysts have projected that the true going forward inherent value of the company is worth at least $140 per share. Further, the stock has recently traded as high as $121.97 per share.

If you are a shareholder of Furiex and would like additional information regarding this matter at no cost or expense please contact us toll free at 1-877-772-3975 or contact us via our website.

Tripp Levy PLLC represents individual and institutional shareholders and, along with its affiliates, has recovered billions of dollars for shareholders in similar actions around the globe. Attorney advertising. Prior results do not indicate a similar outcome

Investigating the acquisition of Zalicus Inc.

Tripp Levy PLLC investigating the acquisition of Zalicus Inc.

April 16, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm announces that it is investigating the acquisition of Zalicus Inc. on behalf of its shareholders. Zalicus Inc. and Epirus Biopharmaceuticals, Inc., announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals, Inc., and will operate under the leadership of the Epirus management team. Zalicus shareholders will only own approx. 14% of the new company.

The investigation concerns whether the board of directors of Zalicus breached their fiduciary duties by not engaging in a full and fair auction to insure that shareholders obtained the maximum value for their shares. If you are a shareholder of Zalicus and would like additional information regarding this matter at no cost or expense including how you can join with other shareholders who are seeking a higher price please contact us toll free at 1-877-772-3975 or contact us via our website.

Tripp Levy PLLC is a leading national law firm that along with its affiliates have recovered billions of dollars for shareholders around the globe. Attorney advertising. Prior results do not indicate as similar outcome

Buyout Of Autonavi

Buyout Of Autonavi – Law Firm Seeks Higher Price For Shareholders

Tripp Levy PLLC, a leading national securities law firm announces that it is investigating the acquisition of AutoNavi Holdings Ltd. in connection with the buyout of the company by Alibaba Group. Pursuant to the merger agreement, AutoNavi shareholders will only receive US$5.25 in cash per ordinary share of US$21 in cash per ADS. Alibaba currently owns over 28% of AutoNavi’s shares.

The investigation concerns whether Alibaba as a significant shareholder and the board of directors of the company are breaching their fiduciary duties to shareholders by not engaging in a full and fair process to sell the company so that shareholders receive the maximum value for their shares, whether there is a conflict of interest and whether the price of $21 is unfairly low.

If you are a shareholder of AutoNavi and would like additional information regarding this matter at no cost or expense please contact us toll free at 1-877-772-3975 or contact us via our website.

Tripp Levy PLLC and its affiliates represent institutional and individual shareholders and have recovered billions of dollars for shareholders around the globe. Attorney advertising

Buyout of Zygo

Buyout Of Zygo – Law Firm Seeks Higher Price For Shareholders

April 11, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Zygo Corporation on behalf of its shareholders. Zygo announced that it has entered into a definitive merger agreement under which Ametek Inc. will acquire all the outstanding shares of Zygo for $19.25 per share.

The investigation concerns whether the board of directors and senior management acted in the best interests of shareholders and not for their owns self interests in selling the company, and whether the price of $19.25 is unfairly low. Indeed, Zygo has over $90 million in cash worth $4.79 per share and no long term debt and the price of $19.25 is less than 2x the company’s book value per share. Further, the Chairman of the board and CEO have agreed to vote their shares in favor of this buyout.

If you are a shareholder of Zygo and would like further information regarding this matter at no cost or expense including how you can join with other shareholders seeking a higher price please contact us toll free at 1-877-772-3975 or contact us via our website.

Tripp Levy PLLC and its affiliates have obtained billions of dollars for shareholders in similar actions around the globe. Attorney advertising. Prior results do not indicate a similar outcome.

^